July 2018

3

4

5 5 6 7

8

9 9

10 10 11 12 13 14 15 15

16 17

18

19

20

21 22 23

24

25 27

TABLE OF CONTENTSLegal Disclaimer

Abstract

1. Executive Summary Identifying the problem in healthcare and how Kinect will address Medical data: the heart of the ecosystem and how it solves the problem Market overview of healthcare in emerging economies 2. Problem: No Big Data and Inefficient Systems

3. Solution Blockchain technology Kinect re-energizing the healthcare landscape Introducing the three elements of Kinect Kinect ecosystem • KinectHUMAN: data collection and financing • KinectHUMAN: system functionality • KinectAID: improving philanthropy and health investment • KinectNOW: reward system • KinectNOW: system functionality

4. Token Economy – Drivers of Token demand How tokens will be used in the ecosystem 5. Business Model

6. Roadmap

7. Revenue Model

8. Token Economics Usage of funds KCT token timeline

9. Blockchain Technology Considerations

10. The Team Advisors

 2

LEGAL DISCLAIMERThis whitepaper is for information purposes only and may be subject to change. We cannot guarantee the accuracy of the statements made or conclusions reached in this whitepaper and we expressly disclaim all representations and warranties (whether express or implied by statute or otherwise) whatsoever, including but not limited to:- any representations or warranties relating to merchantability, fitness for a particular purpose, suitability, wage, title or non-infringement;- that the contents of this document are accurate and free from any errors; and - that such contents do not infringe any third-party rights.

We shall have no liability for damages of any kind arising out of the use, reference to or reliance on the contents of this whitepaper, even if advised of the possibility of damages arising.

This whitepaper may contain references to third party data and industry publications. As far as we are aware, the information reproduced in this whitepaper is accurate and that the estimates and assumptions contained herein are reasonable. However, we offer no assurances as to the accuracy or completeness of this data. Although information and data reproduced in this whitepaper are believed to have been obtained from reliable sources, we have not independently verified any of the information or data from third party sources referred to in this whitepaper or ascertained the underlying assumptions relied upon by such sources.

As of the date of publication of this whitepaper, KCT tokens have no known or intended future use (other than on the Kinect Platform, as more specifically defined in this White Paper).

No promises of future performance or value are or will be made with respect to KCT Tokens, including no promise of inherent value, no promise of continuing payments, and no guarantee that KCT Tokens will hold any particular value. Unless prospective participants fully understand and accept the nature of the Kinect Platform and the potential risks associated with the acquisition, storing and transfer of KCT Tokens, they should not participate in the KCT Token Sale. KCT Tokens are not being structured or sold as securities or investments. KCT Tokens hold no rights and confer no interests in the equity of the company. KCT Tokens are sold with an intended future functionality and utility on the Kinect Platform and all proceeds received during the Token Sale may be spent freely by Kinect on the development of its business and the underlying technological infrastructure.

This whitepaper does not constitute a prospectus or disclosure document and is not an offer to sell, nor the solicitation of any offer to buy any investment or financial instrument in any jurisdiction. KCT Tokens should not be acquired for speculative or investment purposes with the expectation of making an investment return.

No regulatory authority has examined or approved any of the information set out in this whitepaper. No such action has or will be taken under the laws, regulatory requirements or rules of any jurisdiction. The publication, distribution or dissemination of this whitepaper does not imply that applicable laws or regulatory requirements have been complied with.

The Token Sale and/or KCT Tokens could be impacted by regulatory action, including potential restrictions on the ownership, use, or possession of such tokens. Regulators or other competent authorities may demand that we revise the mechanics of the Token Sale and/or the functionality of KCT Tokens in order to comply with regulatory requirements or other governmental or business obligations.

 3

Kinect will change the landscape of healthcare delivery and funding in emerging markets.  The Kinect token-based economy will drive improvements in health outcomes and lift the efficacy and transparency of the $US400bn (+) donated each year to countries in need. All funds can be channelled through the Kinect platform in tokens, enhancing security and transparency. Every patient visit is captured electronically building a valuable database of medical information that is purchased (with tokens) by large multinational corporations. This drives demand for tokens and enables the medical record system to be provided at NO COST to end users.

Our token economy will catalyse behavioural changes in the patient/carer system by incentivising testing, treatment adherence and record keeping. Donors from around the world will be able to zoom in on their donations to understand exactly the impact of their donations. Distributed ledger technology makes this possible by solving storage, security and accountability issues and delivering at lower costs and greater efficiency than ever before possible.

ABSTRACT

 4

EXECUTIVE SUMMARYThe Kinect Token (KCT) is the new digital cryptocurrency for healthcare delivery and health investment applications. It will be the catalyst to drive major behavioral change in disease management and acquire unparalleled quantities of quality medical and consumer data that is highly valued by both commercial and donor organizations. The KINECT blockchain engine drives major improvements in health outcomes of both emerging and first world countries and provides the health information on a national scale (big data), to improve the marketing and clinical trial efficiencies that pharmaceutical and other medical research companies require, but struggle to receive inexpensively and in good time. The building block of this revolution is the individual Electronic Health Record (EHR) created at the point of patient treatment. Stored securely on the blockchain, this single view of the patient is accessible anywhere and updated over time giving a total view of a patient’s health status and aggregates into the big data picture the pharmaceutical and health related industries demand.

Annually $US410 billion dollars are donated to charities and to improve the health of third world countries This aid comes from Governments and organisations such as the Global Fund and the Gates Foundation and private individuals. In 2014 1.4 billion individuals worldwide donated to international charities. One of the major challenges is the difficulty in monitoring where the aid goes and measuring the improvements in health that result. Often the goals of improving health are undermined by patients who lack motivation or healthcare workers who are overworked and under resourced. KinectNOW provides a first of its kind tool to motivate both patients and healthcare workers to change their behaviour to improve health outcomes.

Kinect Token (KCT) incentives can be used to align a country health care goals to the behaviours of both medical practitioners and patients, for the first time. Improved quality of health treatment and outcome data in turn creates greater confidence for Global Donors and Governments to invest on funding healthcare, through the Kinect blockchain engine, knowing that the risk of wastage or inefficiencies are greatly reduced.

Governments, Pharmaceutical Companies, Multinational Corporations, Insurance Companies and Non-Governmental Organisations (NGOs) will purchase access to this strategically important health data using the Kinect Token (KCT). These customer purchases drive the KINECT blockchain engine and fuel the resultant KCT crypto-economy. KINECT will leverage its considerable experience in global healthcare and financial markets to provide the ‘missing link’ between healthcare investment from Governments and Charitable Organisations and the on-the-ground delivery of healthcare. Current roadblocks and bottlenecks that impact on the effective delivery of healthcare and achieving health outcomes will be addressed, developing a complete “dollar-to-delivery” ecosystem.

 5

MEDICAL DATA AT THE HEART OF THE ECOSYSTEM

KINECT is a pioneer to capture and store vast quantities of real-time, real-world data through the highly secure blockchain technology. We are able to capture and provide this data on a de-identified basis in full compliance with US HIPAA health standards (the world standard). The commercialisation of this data funds further expansion of the KINECT ecosystem across the African Continent and eventually Asia and Latin America, at no cost to the patients, health facilities. Governments - Big Pharma and other data users provide the funding (less the Kinect platform fees paid in KCT) in return for access to the data for R&D purposes.

Accelerating data collection at country level. Typically, it can take many years to roll out a national electronic health record across an entire nation. By utilising sophisticated atomisation scanning technology, the Kinect team will be able capture and sort all current paper based medical records providing a critical mass of de-identified medical data to drive revenue and token utilisation. In contrast, participating international donor organisations will be able to receive real time data on the progress of their sponsored projects as soon as Kinect is made available to their on-the-ground personnel delivering the treatment.

Already operating in Africa, the Kinect Team has more than 60 years of combined healthcare, technology and finance experience across the globe. Our management team consists of successful healthcare entrepreneurs, doctors and developing market finance specialists experienced in building and developing catered healthcare solutions. For the past three years our previous health-tech company provided custom cloud-based EHRs that tackle disease burdens in Africa and Asia. We have worked alongside African governments (Ministries of Health, Presidents Offices…) and Global Donors in Switzerland and the US (Gates Foundation, Global Fund, UNAID…), placing us in a privileged position to fully appreciate the current challenges and comprehensively implement the Kinect world-first solution to global health problems. KINECT integrates the properties of blockchain technology to elegantly solve many of the problems that we encountered in these countries, greatly improving cost effectiveness and outcomes in the healthcare landscape.

 6

MARKET OVERVIEWHealthcare expenditure is currently greater than 10% of GDP in most countries and forecast to rise to $US 8.7 trillion by 2020 According to the World Health Organization infectious diseases remain a major global health risk. Africa has 24% of the global disease burden with only 3% of the global health workforce and 1% of global healthcare expenditure.

Major international aid organizations e.g. The Global Fund, Unicef and the Gates Foundation donate billions of dollars each year to fight HIV, Malaria, Tuberculosis and other diseases.The high incidence of infectious disease and poor infant mortality mean that the life expectancy in some African countries is less than 55 years.

HIV affects 36.9 million people globally, with over 70% of them in Africa. In 2015, 2 million more people were infected with HIV and in 2016 more than 20 million were still not receiving anti- retroviral treatment. Africa accounts for almost two thirds of new HIV infections.90% of all Malaria cases are in Africa with 450,000 deaths in 2016.

• Childhood mortality rates are highest in Africa.• 15,000 children die every day.• 1 in 13 children die before their 5th birthday.• More than 50% of deaths are preventable and due to disease such as pneumonia, malaria, diarrhoea.

Africa is one of the most rapidly growing health markets that will be worth $US 65 billion by 2020 (Mckinsey june 2015) Pharmaceutical companies and other corporations spend billions of dollars each year to purchase market sales data to inform their marketing approaches.

The health information market is currently estimated at $US 54 billion. IMS, a company that that sells such data to pharmaceutical companies had revenues of $US 2.9 billion in 2015, and grew revenue in emerging markets by 32%.The difficulties in currently obtaining accurate market data in Africa, suggests there will be strong demand for Kinect BIG DATA.

Over $US 400 billion is donated around the world each year from individual charity donors, governments and NGOs.There were more than 1.4 billion individual donors last year. Fundraising for charities is a very costly and time-consuming affair. It is not uncommon for a charity to spend more than 30% of their donations on fundraising and administration.

There are over 500 million holders of mobile phone accounts in Africa. Last year sales of smartphones in Africa grew by 50%.

Research organizations can spend up to $US 10 billion dollars to develop a new drug. A significant part of this coast is clinical research. Pharma companies are increasingly looking to Africa and Asia to conduct research to reduce costs.

Currently close to 50% of all clinical trials are delayed due to problems recruiting suitable patients. Fundraising for charities is a very costly and time-consuming affair.

 7

PROBLEM – COMMON DENOMINATOR: NO BIG DATA & INEFFICIENT SYSTEMSLast year sub-Saharan African countries received US$36bn in medical foreign aid, the most out of any region, according to the OECD’s preliminary estimates. South and central Asia received $21bn.

A major focus is an attempt to eliminate infectious diseases (e.g. HIV, TB, Malaria) and narrow the gap to first world health standards. Many challenges limit the donor organisations’ confidence to invest. Often the neediest countries have suffered from reduced support as a consequence.

Individual donors to charities currently have little or no information as to where the money they donate actually ends up, nor whether the aid programs utilising their donations are effective. A significant percentage of donations are traditionally diverted as commissions to fundraising organisations, limiting the impact.

Pharmaceutical companies and other organisations have also identified emerging economies in Africa and Asia as major growth opportunities but have little data to inform their marketing approaches.

Clinical Trials. Pharmaceutical companies and research organisations look to emerging countries to conduct costly medical research in order to manage R&D costs, however recruiting suitable patients to participate in the trials can be very costly.

Paper-based record systems are not efficient. In many cases due to poor record keeping and naming patients, medical staff have difficulty establishing a patient’s unique identity. It is often impossible to keep track of what medicine has been given to whom. Patients are able to attend multiple medical centres and collect additional medication (to be on-sold or otherwise). It was reported by a Senior Health Official in the Democratic Republic of Congo that a desktop audit of paper systems revealed 30% duplication of treatment.

Leakage, or misappropriation of medical supplies is a serious issue in emerging economies, in Africa and Asia with up to 20% of the already limited medical supplies not reaching its intended destination due to poor supply chain tracking, theft and inefficiencies.

Patient Monitoring and surveillance. Building an accurate understanding where medication ends up and how well it improves health outcomes is extremely difficult. Paper systems for recording and tracking, including manual sharing (e.g. by mail) means accurate analysing medical data and treatment outcomes is difficult.Patient compliance (sticking to treatment) poor compliance leads to treatment failure and provides the conditions for emergence of antibiotic resistance. This is a major issue in fighting communicable diseases (such as tuberculosis). Pharmaceutical companies are strongly focused on patient compliance in chronic disease such as diabetes and high blood pressure and cholesterol as it will increase revenue and as a way to improve effectiveness.

The management of acute infectious disease outbreaks such as the Ebola virus outbreak in West Africa (2014–2015), the emergence of the Zika virus syndrome in (2015–2016), and multi-country yellow fever outbreaks in Africa (2016), has highlighted major challenges. Gaps in risk tracking and mass reporting and response systems during these epidemics and other health emergencies are limited by outdated systems.

Low investment in health system. Although highly effective, the high costs of introducing and supporting any modern medical record data systems, combined with concerns about security and patient confidentiality means governments are reluctant to fund initiatives.

Current paper-based record systems are highly inefficient and result in wasted resources (Money).

 8

BLOCKCHAIN TECHNOLOGY – NEW SOLUTIONIncorporating blockchain and leveraging the new economic opportunities afforded by the technology (decentralisation, immutability, security and accountability) can lead to dramatic improvements in healthcare. Kinect provides a powerful new tool for improving healthcare systems and can transform the health infrastructure in developing and developed world countries alike. To understand more about the technology, follow this link to the Satoshi Whitepaper.http://static.bitcoingroup.com.au/wp-content/uploads/2015/09/Satoshi-White-Paper.pdf

Initial customer feedback particularly from governments and NGOs is a strong preference for a private blockchain between participating organisations, governments, charities, etc. Additionally, there could well be commercial advantage in developing a bespoke blockchain for Kinect.

Blockchain (also called distributed ledger), the technology enabling cryptocurrencies like Bitcoin, Ethereum and NEO, is pulling us into a new era of openness, decentralization and global inclusion. It leverages the resources of a global peer-to-peer network to ensure the integrity of the value exchanged among billions of devices without going through a trusted third party. Unlike the internet alone, blockchains are distributed, not centralized; open, not hidden; inclusive, not exclusive; immutable, not alterable; and secure. Blockchain gives us unprecedented capabilities to create and trade value in society.

Blockchain emerged in the wake of the global economic crisis, when a pseudonymous person or persons named Satoshi Nakamoto released a new protocol for “A Peer- to-Peer Electronic Cash System” using a cryptocurrency called Bitcoin. Cryptocurrencies (digital currencies) are different from traditional fiat currencies because no government issues or controls them. They’re not saved in a file somewhere; they’re represented by transactions recorded in a blockchain – like a global spreadsheet or ledger, which leverages the resources of a large peer-to- peer bitcoin network to verify and approve each bitcoin transaction. Satoshi’s protocol established a set of rules – in the form of distributed computations – that ensured the integrity of the data exchanged among billions of devices without going through a trusted third party.

Some blockchains, like the one that uses bitcoin, are distributed: running on computers provided by volunteers around the world; there is no central database to hack or shut down. We can send money and any form of digitized value – from commodities, stocks and bonds to intellectual property, art, music and even votes – directly and safely between us without going through a bank, a credit-card company, PayPal or Western Union, social network, government or other middleman. Of course, this does not mean that middlemen will disappear. Rather the technology provides profound opportunities to create new value and enter new markets.

Blockchain is encrypted: it uses heavy-duty encryption involving public and private keys (Public key = your address like a bank or house; and Private key = your assets) to maintain virtual security. Within minutes or even seconds, all the transactions conducted are verified, cleared and stored in a block that is linked to the preceding block, thereby creating a chain. Each block must refer to the preceding block to be valid. This structure permanently timestamps and stores exchanges of value, preventing anyone from altering the ledger.

Blockchain technology can be used in a variety of settings (both public and private) where one desires a validated, unalterable, time-stamped, and decentralized ledger. We leverage these blockchain properties at Kinect to streamline access management for Electronic Health Records (EHRs), change patient and doctor behaviour and provide transparency to the international donor community.

 9

THE SOLUTION: KINECT RE-ENERGISING THE PERFORMANCE & FINANCING OF THE HEALTHCARE LANDSCAPEKINECT has taken a holistic view of addressing healthcare reform re-imagining the entire ecosystem with no single point of failure. How do we achieve this? The three elements of KINECT re-envisions the way health and health data is managed at the same time as how health systems are financed. The goal is re-routing current spending on market health information data and analysis by simplifying these processes through the use of blockchain technology. By re-engineering the relationship between health service provision and data utilisation, Kinect is able to maximise delivery and monitoring of healthcare in low, middle and high-income countries globally AT NO COST to patients, medical staff and health facilities.

At the heart of Kinect is the individual patient record. These de-identified records can be aggregated, analysed and then utilised by many different stakeholders. Patient and carer behaviour can then be rewarded to drive improvements in health outcomes.

The KINECT team is leveraging significant more than three years’ experience in Africa working alongside Ministries of Health, Heads of Infectious Disease programs and IT departments to understand their challenges and needs. The Kinect blockchain ecosystem expands and enhances our previous efforts, to deliver a solution that will dramatically change the healthcare landscape.

THREE ELEMENTS OF KINECT

 10  10

KINECTHUMAN: THE DATA COLLECTION RE-ENERGISING HEALTHCARE AND ITS FINANCINGKinectHUMAN is an Electronic Health Record (EHR) platform built on blockchain technology with a simple User Interface.

KinectHuman: re-Imagining the complete Healthcare ecosystem as a self sustaining/self perpetuating, “funder to end user” solution that eliminates points of failure in existing models. Replacing current paper-based medical records will address many of the barriers to improving health outcomes, this includes duplication of records, loss of stock/medicine, poor patient compliance, accurate recording and tracking of treatments and results. Current EHR systems, where available, do provide benefits but face serious challenges including ongoing costs of hosting, maintenance and maintaining security to protect sensitive personal medical information.

The KinectHUMAN blockchain-based EHR solution eliminates the process of finding and recruiting individuals who meet eligibility criteria for clinical trials. With KinectHUMAN all inaccuracies involved with collecting precious data assets dissipate as individual patient identification functionality eliminates duplication of patient records. The KinectHUMAN advantage has the potential of generating industry savings into the billions over time.

Patients In Africa and Asia will be able to use the system at NO COSTIn low income countries, this can be the difference between treatment success and failure.Patients will be able to access their own medical record and KCT coin rewards provided at Kinect terminals placed in medical clinics and pharmacies, or on their own devices.

Kinect Human creates a standardised, portable medical record. It is a single view of the patient, accessible by doctors, pharmacy, laboratories and the patient. The unique patient ID avoids duplication of treatment.Standardised (identified) high-quality patient data will be easily accessed for BIG DATA applications.

Whilst provided for free to end users, the KinectHUMAN platform enables cross-organisational sharing of untampered data that can be purchased with KCT tokens. Adoption will be accelerated by the provision of an easy to use and adaptable platform and an ecosystem that incentivises both healthcare workers and patients. KinectHUMAN collaborates seamlessly with the token reward system, KinectNOW.

 12

KINECTHUMAN: KEY SYSTEM FUNCTIONALITY:Kinect management forecast that by the end of Q1 2019 the system will have over 1 million patient records in up to five countries on the African Continent, as existing paper-based patient records are integrated into a database using custom atomisation scanning technology.

• Cloud-based EHR, powered by an innovative blockchain solution with an easy to use interface, designed by doctors for optimal

workflow in consultation with several African Ministries of Health

• Mass scanning of existing paper-based records for rapid expansion of patient data base

• Zero cost to users promotes wide spread system adoption

• Blockchain ecosystem eliminates complex administrative and management issues

• The EHR integrates with other Government and NGO systems

• Location specific adaptability with multi-Language capability and country-specific units of measure configuration

• Collection of detailed patient data over multiple assessment, management, planning and follow-up stages

• Highly secure solution protecting private medical records maintaining data integrity, in compliance with HIPAA guidelines

• Automated patient reminder/follow-up to address compliance

• A single view of the patients integrating pharmacy, clinic and laboratory

 13

KINECTAID: TRACEABILITY AND TRANSPARENCY IN PHILANTHROPY AND HEALTH INVESTMENT KinectAID provides a philanthropic donation platform that yields absolute transparency in allocation of funds, featuring complete end-to-end tracking of contributions through blockchain technology. KinectAID allows users to choose which project their funds will be pledged to and directly witness the impact their funds are having on any given Kinect initiative (or other approved charity). This is made possible by utilising the de-identified individual electronic health record of each sponsored individual. KinectAID will showcase various projects, NGO and partner charity initiatives.

Q4 2018 - KinectAID community members including the Gates Foundation, Global Fund, and StopTB will receive 7% of the Token Allocation in KCT to invest into projects where the KinectHUMAN EHR will be deployed. Ensuring from DAY ONE there will be a high degree of token utilisation and rapid expansion of the KinectHUMAN EHR and Kinect ecosystem.

Increases potential impact from charitable giving. All donations are made in KCT, increasing the potential for growth in the value of the donation and therefore also return on investment (ROI). For example, the Global Fund may allocate US$30m over 6 months to HIV programs in Sudan and it has these funds invested as KCT tokens. The increasing value of the KCT tokens purchased by medical research (Big Pharma, Insurance, Corporates with Social Responsibility Programs) and consumer marketing companies would lead to an increase in token value over a two-year period, so this US$30m could be US$33m in value by the time it is deployed. This additional $3m would provide additional funding to HIV or any other humanitarian initiatives, at the Global Funds’ discretion.

Together the United States, China, United Kingdom, Russia, Australia, and Switzerland accounted for US$410.71 billion in charitable donations in 2014 1. Charities often spend a significant percentage of their donations on fundraising (up to 30%). KinectAID streamlines the middlemen, meaning the majority of this 30% will make its way to the targeted people in need.

1 In 2014, Australian charities had a total income of $103 Billion, of which donations and bequests comprised $6.8 Billion (or 6.6%). http://www.philanthropy.org.au/; UK: The estimated total amount donated to charity by UK adults in 2014 was £10.6 billion. https://www.cafonline.org/ ; Switzerland: The estimated value of private donations to Swiss charities was $1.8 billion in 2014. https://ceps.unibas.ch; Russia: Total given in 2015 was $2.3 billion; total give in 2014 was $2.5 billion. https://www.cafonline.org/; China: Total charitable donations in China were $13.2 billion in 2012, or 4 percent of all U.S. donations. http://thediplomat.com/

 14

A REWARD SYSTEM THAT DRIVES THE DESIRED BEHAVIOUR IN PATIENTS AND MEDICAL STAFF TO IMPROVE HEALTH OUTCOMES AND ASSIST WITH PATIENT ADHERENCE Tokens reward systems have been highly effective since the 1990s in the US to drive behavioural change in substance abuse and mental health management. Moreover, recent research by Harvard neuroscientist Dr Tali Sharot also supports the use of rewards-based systems to incentivise behaviour.

Stakeholders will identify critical behavioural objectives that can improve health, e.g. presenting to the clinic for a HIV test, completing a course of TB medication. It has the potential to have a major impact on treatment initiation and continuation in large ‘at risk’ populations of both chronic and communicable diseases.

KinectNOW will provide a method to offer rewards in ways best suited to end user populations. KinectNOW is currently evaluating the option of telecommunication companies giving people the chance to claim their rewards in phone credit and with local vendor partners to claim retail consumer items, particularly health related products.

Kinect is exploring alliances with third-world mobile banking providers such as The Gates Foundation’s Mojaloop payment platform and other innovative blockchain-powered mobile payment systems such as WALA, which aim to extend basic financial services to the 2 billion people worldwide who lack access traditional financial services.

KinectNOW KEY SYSTEM FUNCTIONALITY:• Tokenised incentive program for patients and health professionals driving behavioural changes that increase treatment

adherence and productivity• Patients and health practitioners can sell tokens back into the Kinect network to ‘cash out’ their reward for improved health

outcomes into fiat currencies• Use of Kinect tokens at local vendor partners and telecommunications partners (mobile minutes)• Purchaser uses their KinectNOW APP to scan the QR code and the payments are processed practically instantaneously

(potential partnership with systems such as Mojaloop and Wala)• Incentive system promotes wide spread KinectHUMAN system adoption

 15

THE TOKEN ECONOMYThe Kinect token KCT will enable the development of a complete “dollar-to- result” ecosystem that provides auditable, targeted and effective population health management linking charitable organisations, governments and pharmaceutical companies to achieve measurable and efficient results. Fraud, corruption and product loss will be significantly reduced and ultimately eliminated with widespread adoption.

There will be many users of the token driving demand

a. Charitable donations and health investments (Global Donor Organisations) can be made and converted into KCT, from fiat currencies and other cryptocurrencies like Ethereum (ETH). These entities must retain a minimum monthly balance of KCT for ongoing database access

b. KinectAID – donations made through the App are converted from fiat currencies or other cryptocurrencies into KCT. This provides full traceability of the transaction from donation to ultimate result, whichever charitable program donors choose

c. Incentive program (KinectNOW) for health professionals and patients for adhering to treatment programs, all payments in KCT monitored through the open-source, secure (KinectHUMAN) distributed ledger EHR.

d. Payment for medical supplies and services by both end users and medical practitioners (supply-chain tracking)

e. Biomedical research, Pharmaceutical R&D departments pay licence fees for data usage to assist is recruiting patients for Clinical Studies and must retain a minimum KCT balance

f. Health Insurance companies – while still relatively nascent, there is a growing level of private health insurance in the third-world, with middle and upper classes ensuring families are protected given the lower standard of public health care. Health insurers wanting access to more accurate data to assess patient premiums can, at the patients consent, access this information through purchasing KCT

g. Multinational companies and marketing agencies – for those patients that ‘opt-in’. These entities must also retain a minimum KCT balance for access to the database

h. Private Hospitals and clinics – may eventually adopt the KinectHUMAN EHR and KinectNOW incentive program for

patient adherence and data collection

 16

HOW THE TOKENS ARE USED

 17

BUSINESS MODEL Rapid market acceptance of Kinect is essential to achieve a critical mass of patient data. This will be achieved by delivering a No Cost, easy to use system.

Atomisation scanning of existing paper-based patient records puts data into appropriate digital fields in the KinectHUMAN database. This will be undertaken in certain priority locations to drive rapid collection of quality data. Kinect forecasts we will have over 1 million patient records in the system by the end of Q1 2019.

Early and broad adoption of Kinect at a country level will be driven by key stakeholders, Government health departments and major donors, e.g. Global Fund who will reap the benefits of the system, will support uptake.

Incentivize Pharmaceutical and NGO community to adopt early. Community tokens retained from the ICO will be allocated at the discretion of the Kinect Client Committee to priority NGOs and pharmaceutical companies expected to be amongst the largest data users.

Expansion of the KinectHUMAN EHR. Expansion of the EHR is critical to expanding the dataset Kinect will deploy significant funds from the ICO to initiate the free KinectHUMAN EHR projects ensuring rapid uptake of the system and immediate data value.

Rapid consumer adoption of the KinectAID App. The 1.4 billion individual donors to charity are a key target as they will play a major role in token utilisation building market awareness, uptake and generating PR opportunities. Online and physical media marketing campaigns will initiate consumer downloading and usage of the App. Marketing campaigns will focus on effective real time tracking of Kinect project initiatives (dollar-to- result monitoring) and the ease and variety of charitable project selection.

Drive patient and health professional enrolment in KinectNOW through early incentives Clinical evidence suggests that financial rewards are an extremely potent motivator for driving behaviour change in the health arena.On-the- ground implementation teams will communicate the monthly rewards to health professionals. Marketing campaigns will focus on third world countries where incomes are extremely low, uptake is forecast to be rapid amongst patients.

Kinect will work in partnership with aid organisations and governments to ensure tablets and other devices for data capture are available in areas of high traction that are less well resourced. KinectAID programs can also contribute.

• barrier Token Driven. Rewards Driven

Database Size KCT Price

>1 millionpatient records 1Q19

KCT price increases more than size as more users join platform

Increased size of KINECT cross-demographic population database =Increased value and utility of data=Broader range of users =Increased demand for KCT

KCT Price as size of Database increases

 18

ROADMAP

 19

REVENUE MODELValue-added data licensing (primary)Data consumers (pharmaceutical, corporates, NGOs, medical research) need to maintain minimum balances in order to retain data usage licences and monthly fees will be paid in KCT and deducted directly from enterprise KCT accounts. Kinect will directly use this token revenue for 1) fuelling ecosystem use 2) KinectNOW incentive program 3) reserve tokens potentially for resale.

Revenues received in KCT Per Annum Revenues (# institutions) paid in KCT

Database Access licence fees

Monthly (USD) per

institution1 year 3 years 5 years 10 years

Pharmaceutical 150,000 1,800,000 5,400,000 9,000,000 18,000,000

NGOs 37,500 450,000 1,350,000 2,250,000 4,500,000

Universities & other medical research 37,500 450,000 1,350,000 2,250,000 4,500,000

Health-related consumer marketing 225,000 2,700,000 8,100,000 13,500,000 27,000,000

Consumer marketing - other 262,500 3,150,000 9,450,000 15,750,000 31,500,000

$8,550,000 $25,650,000 $42,750,000 $85,500,000

 20

KINECT TOKEN ECONOMICSKinect is a limited supply token

• Kinect will issue a total of KCT 725M tokens• Fixed Amount - no more tokens will be issued• Q3 2018 - Key community members including the Gates Foundation, Global Fund, and StopTB will be allocated 7% of the

Token allocation in KCT to invest into projects where the KinectHUMAN EHR will be deployed. Ensuring from onset there will be a high degree of token utilisation and rapid expansion of the ecosystem

• Unused tokens will accurately be gifted to investors who failed to achieve ‘Whitelist’ status in the ICO and are labelled ‘waitlisted’ and to the KINECT community on Social media platforms

• All tokens to be created in Genesis Block

• 12% of tokens will be retained by Kinect Bank to ensure a stable and liquid transaction market for KCT

KinectAID

Donations through the App 6.50%

Donations from NGOs 0.25%

Donations from Corporates 6.50%

 21

USAGE OF FUNDS RAISED FROM ICOFunds raised during the Pre-ICO and ICO phase will be progressively deployed according the allocations below. The majority of the expenditure will drive rapid growth of the number of patients in the database through geographic penetration and integration into existing systems. This includes associated expenditure including staffing requirements and infrastructure spend.

 22

KCT TOKEN TIMELINEThis program involves several offline rounds of investment. We are also considering initiating a series of investments online. The options, date and time of online round will be included in the document as soon as detailed Information on the program is available.

TOTAL KCT TOKEN SUPPLY: 725MRESERVED: 319MAVAILABLE FOR SALE: 406M

PRE-SALE

50% discount for pre-sale and first 70m receive an additional 20% token bonus

TOKEN SALE

Availability of tokens will depend on amount sold during pre-sale

Start date 15th August 2018, (9am EST/6pm PST/10pm UTC)

End date 30th September 2018 (5pm EST/2am PST/6am UTC)

Discounted price US$0.09

Accepted crypto-currencies NEO, Ethereum, Bitcoin

Accepted fiat currencies Varies by jurisdiction

Sale will end at one of these events 191M tokens sold / Sale period ends

Start date 1st October 2018, (9am EST/6pm PST/10pm UTC)

End date 1st November 2018 (5pm EST/2am PST/6am UTC)

Price US$0.18

Accepted crypto-currencies NEO, ETH, BTC

Accepted fiat currencies Varies by jurisdiction

Sale will end at one of these events All tokens sold / Sale period ends

 23

TECHNOLOGY CONSIDERATIONSBlockchain TechnologyBecause of the sensitive nature and requirements of healthcare, existing blockchain systems are not adequate for healthcare.The goal of Kinect is to create a blockchain system that can pass legal and consensus requirements of healthcare by ensuring better data integrity, encryption and by proving a providing a validation system, KINECT ID,  to ensure all is compliant.Kinect will build a distributed ledger network to support a decentralised, safe and trusted healthcare ecosystem that provide’s over 100,000 transaction per second payment-for-outcomes, immutable records, data management and storage regardless of clinical affiliation. This will provide a care pathway transparency and near real-time analytic across facilities and companies. This results in greater security, efficiencies, and improved risk management, driving better patient care and a better provider experience.This is accomplished via an update to data integrity and security system and addition of an executive governance system for node validation.

 24

THE TEAMKinect team members have collectively over 60 years healthcare, technology and emerging market experience. Importantly, as with any industry, business development for successful market entry is already accomplished through our existing, well established networks.

Toby Carroll, Founder & Executive Chairman, Last three years working with cloud-based EHRs across Africa, 20 years experience working in the global Investment Banking at organisations such as Morgan Stanley, HSBC and Macquarie Bank and Private Equity industries, focusing on Emerging Markets. Utilising this experience and established Governmental relationships led to the creation of Kinect, enabled by the superior advantages of blockchain technology. He has over 20 years experience working in the global Investment Banking and Private Equity industries, focusing on Emerging Markets across Asia, Middle East, Eastern Europe and Latin America. He has specialized in cross border operations and management structures and liaising with senior level Government and Managerial Executives and a wide range of stakeholders. Toby has invaluable Governmental contacts and an established network across Africa to enable Kinect to successfully implement its platform.Linkedin: https://www.linkedin.com/in/toby-carroll-cfa-kinect/

Guy Newing, Founder & Chief Executive OfficerFounder and CEO of Hexcel Global a pioneer in developing “cloud” based Electronic Health Record systems for third world countries.Successful healthcare entrepreneur who redefined the pathway for diagnosis and treatment of sleep apnoea in Australia and buildingand the largest ambulatory (in home) sleep testing organization in the country.Developed, patented and manufactured novel technology to protect mobile phone users from radiation. Twenty years (+) experiencein healthcare sales and marketing consulting to and working for Multinational Pharmaceutical , including Merck and Pfizer  in Australia and Asia focusing on building excellence in customer marketing.Linkedin: https://www.linkedin.com/in/guy-newing-a17106b/

Omar Al-Sobky, Blockchain and Business Advisor.Omar has been in the crypto world since 2010 and served as a consultant and investor on many fronts in the world of cryptographic assets. He specialises in business model development, blockchain integration and PR strategies. Omar worked as an Advisor for Consultancy ICO, where he worked on a range of projects such as Asura and many other coins. He is the main blockchain and business advisor for Kinect and World Entertainment Chain.Omar has over 10 years in the Film and Television and promotional/event management industry and is currently running his own business , BitontheSide Promotions, that merges both industries into one. Linkedin: https://www.linkedin.com/in/omaral-sobky/

Dr Adrian Cohen, Chief Medical Advisor Over 30 years experience in the healthcare industry as a practicing physician and business developer, pioneer of Health IT management solutions including Paramedix, MedicalOnline, SkinChex, ConcussionPassport, Founder of GoodHealth Television, MedicalOnline, Immediate Assistants Events, Necksafe, Headsafe. Linkedin: https://www.linkedin.com/in/adrian-cohen-9a65b62/

Sal Shah, Corporate client managerSal has over 20 years of global healthcare experience spanning industry and consulting. He has significant experience operating at senior levels and has worked in a variety of Commercial Strategy and Market Access leadership roles within Pfizer, Sanofi, Roche, IMS Consulting & ICON Plc.His past experience includes leading the joint venture between IMS and Dr Foster Intelligence on big data (RWD) and its utility, he was also previously Head of Private Market, Head of the Pre-Launch Market Access at Roche. Sal was also a member of the Roche European Sub-National Leadership team and was most recently working in Basel (Switzerland) with a group of Global leaders to establish innovative pricing /financing structures for future medicinal assets.Sal was a Director & Principal in the Access consulting practice at ICON Plc and also Global Head of Strategy for the HEOR practice. He is currently CEO of TS Capital Partners Ltd. Linkedin: https://www.linkedin.com/in/saleem-shah-01a89723/

 25

THE TEAMGaston Guernik, Head of UX/UIGaston Guernik is a UX/UI expert with broad experience in app design, product design, service design and brand strategy. Highly passionate about UX excellence, he has a strong belief in designing applications for the human experience and adopts a “end user first” mindset to every project he has been a part of. Throughout his 15 years of experience in the creative industry, he has worked with some of the biggest brands in the world, including Audi, Commonwealth Bank, NSW Government, Schweppes, BMW, Heineken, NSW Rails, etc. Linkedin: https://www.linkedin.com/in/gastonguernik/

Anna Jobsz, Head of CommunicationsSixteen years PR, online marketing and communications experience across a range of clients, from digital start-ups, to boutique brands, to larger scale established businesses. Established expert ensuring stakeholders interests are aligned. Linkedin: https://www.linkedin.com/in/annajobsz/

Mbi Tbetando, African Government Operations ChiefSpent the last three years working with Kinect building political relationships in Cameroon, using a cloud-based EHR HEXCEL platform. Has worked in medical analysis and diagnostics for almost a decade. Prior to that, was a Senior Executive at EurOil/Bowleven and JP Morgan. Linkedin: https://www.linkedin.com/in/mbitabetando/

Craig LynchCraig is a highly experienced IT development/solutions manager and enterprise architect. He has delivered solutions across a range of business and technical domains within Australia, the Asia Pacific region and at global levels, with 29 years experience in the pharmaceutical industry. Craig was Manager, Information Systems within MSD Australia, and later became an IT Director within the Human Health IT division, with global responsibilities for Business Intelligence and Master Data Management enterprise architecture. Linkedin: https://www.linkedin.com/in/craig-lynch-0031374/

Ankur Maheshwari ‘TechRacers’ - Blockchain Developer Ankur comes with more than 15 years of experience in software development. As the Director of Research at Techracers, he has been leading development of multiple products on blockchain like patientory.com, peculium.io, sgpay.org, howdoo.io, triforcetokens.io, monetha.io etc. His experience varies, starting with setting up of entire new engineering and product teams, to leading a geographically distributed and cross-functional team of 100+ developers. Still a hands on programmer, he loves experimenting and believes that technology should be a tool to solve real world problems. Linkedin: https://www.linkedin.com/in/ankur-maheshwari-9ab2a215/

 26

ADVISORSJohn King BurnsMr. Burns serves as Chief Executive Officer and President of NeurSciences LLC, a privately company specializing in artificial intelligence. Mr. Burns has extensive experience in the global resource sector. He serves as an independent director for China Gold International Resources Corp. as Chair and Lead Director of Jaxon Mining Corp. and as an independent director and Chair of the Audit Committee of Simba Essel Energy Inc. Mr. Burns also serves as an advisor to Potomac Asset Management in Frederick, Maryland. Additionally, Mr. Burns serves on the board or as an advisor to other privately held exploration and production, software, process technology and fund management companies in the natural resources, energy and technology industries.

Mark TimneyMr. Mark Timney is a global health care leader, CEO and President serving the biotech and pharmaceuticals industries, with 20+ years of sales/marketing experience, and a record of financial growth and success in designing and executing strategies to achieve market leadership. He has deep expertise in launching key products, leading transformational business development, leading and managing change, developing executive talent, adding shareholder value, and meeting compliance standards together with significant enduring pharma global business relationships Previous roles include President & CEO at Purdue Pharma (2014 – Aug 2017), and Merck President US, Merck & Co leading an organization with $16Bn in sales, 8,000+ employees, overseeing Sales and Marketing, Managed

Markets and Payers within the US Market.

Kenneth Peter JudgeKen Judge OAM ( Order of Australia Medal) works from Monaco with a private investment group where he uses his experience as a corporate lawyer specialising in cross - border mergers and acquisitions, corporate reconstruction and public company/capital markets finance. Mr Judge has broad experience of corporate financial restructurings and mergers and acquisition transactions especially with respect to technology, resource and energy companies. Many of the companies with Mr Judge has been involved operate in emerging and less developed markets including a number of countries across south-east Asia, north and eastern Africa and most of South America. Mr Judge has had an extensive involvement in the Capital Markets of the UK, the US, Canada, Australia, Hong Kong, Peru and Brazil. Nitin MelwaniEntrepreneur with 20+ year experience in emerging markets. Currently runs a Management Consultancy in Dubai and is an enthusiastic early crypto investor. Nitin has been involved with blockchain technology companies for last 2 years and is an angel investor to many of the early startups.

AJ BertenshawAJ Bertenshaw has a lengthy career in working in the innovation and technology space. He founded Serato digital music software in 1998 with Steve West and retired to the board in 2006 and has since returned as CEO in 2015. Prior to that graduated a bachelor science with honours in Auckland. More recently he has been involved with setting up a ‘venture fund’ that focuses on start ups and technology. He is currently working on virtual reality, blockchain and digital music distribution projects.

Ross RamsayCommercial adviser. 25 years plus experience working at a senior level for international businesses including 17 years as a corporate and commercial partner with one of the world’s largest law firms. For 20 years Ross has acted on infrastructure, resource and energy projects in Australia, Indonesia, Vietnam, Singapore, Papua New Guinea and elsewhere in the Asia Pacific region. Tom Neyarapally Thomas A. Neyarapally serves as the Chief Commercial Officer for Sema4, a health information company dedicated to improving the diagnosis, treatment, and prevention of disease through deep data analysis. Tom was previously a member of the founding team and Executive Vice President, Corporate Development at the healthcare analytics company GNS Healthcare, where he led the expansion of GNS’ business from systems biology into the commercial groups within pharma as well as payers and providers Earlier in his career, Tom served as a corporate and intellectual property lawyer at Chadbourne & Parke LLP and Frommer Lawrence & Haug LLP.

 27

CUSTOMER COUNCIL Kinect has relationships with many of the largest global charitable organisations operating to improve health. Relationships established and strengthened over the last three years have enabled Kinect to establish expressions of interest that will ensure the launch of the Kinect ecosystem is successful. These relationships are integral to the utility and increasing value of the token which ultimately drives improved health outcomes. Key relationships are managed by our Head of Charitable Organisations, London, UK.

Kinect’s key Customer Council target members include::I. GLOBAL FUNDII. BILL & MELINDA GATES FOUNDATION III. STOP TBIV. UNAIDV. USAIDVI. TB

 28